Steatosis as a cofactor in other liver diseases: hepatitis C virus, alcohol, hemochromatosis, and others.
Steatosis as a cofactor in other liver diseases: hepatitis C virus, alcohol, hemochromatosis, and others.
复制标题
DOI：
10.1016/j.cld.2007.02.007
复制
发表时间：
2007-02-01
影响因子：
5.1
通讯作者：
Powell, Elizabeth E
中科院分区：
文献类型：
--
作者：
Clouston, Andrew D;Jonsson, Julie R;Powell, Elizabeth E
随着肥胖患病率的上升，有证据表明脂肪肝疾病可以与其他慢性肝病协同作用，加重肝实质损伤。这在慢性丙型肝炎中表现得最好，其中脂肪变性是由病毒和代谢作用引起的。有证据表明，脂肪变性及其代谢异常也会加剧其他疾病，如酒精性肝病，血色素沉着症，以及可能的药物引起的肝病。发病机制似乎与脂肪肝细胞对凋亡的敏感性增加、氧化损伤增强和肝细胞再生改变有关。数据表明，积极管理肥胖可能会改善肝损伤，并减少患有其他慢性肝病的患者的纤维化进展。
As obesity prevalence rises, there is evidence that fatty liver disease can act synergistically with other chronic liver diseases to aggravate parenchymal injury. This is characterized best in chronic hepatitis C, where steatosis is caused by viral and metabolic effects. There is evidence that steatosis and its metabolic abnormalities also exacerbate other diseases, such as alcoholic liver disease, hemochromatosis, and, possibly, drug-induced liver disease. The pathogenesis seems related to increased susceptibility of steatotic hepatocytes to apoptosis, enhanced oxidative injury, and altered hepatocytic regeneration. Data suggest that active management of obesity may improve liver injury and decrease the progression of fibrosis in patients who have other chronic liver diseases.